Loading...
ALXP
ALECR
Market cap103mUSD
Oct 16, Last price  
18,400.00EUR
Name

Eurofins-Cerep SA

Chart & performance

D1W1MN
ALXP:ALECR chart
P/E
19.41
P/S
2.27
EPS
948.15
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
6.62%
Div Yld LY
—
Div Yld TTM
—
Revenues
41m
40,975,031
Net income
5m
4,782,469
CFO

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1989 and headquartered in Vienne, France, Eurofins Cerep SA delivers a broad spectrum of drug discovery support to pharmaceutical and biotechnology enterprises across the globe. The company's specialized offerings include the management of chemical compounds, high-throughput screening capabilities, in vitro safety assessments, optimization of lead compounds (SAR profiling), in vitro ADME evaluations, and in vivo pharmacokinetic (PK) studies. Furthermore, it provides expert services in assay development and design. The organization, originally known as Cerep SA, officially adopted the name Eurofins Cerep SA in June 2014.

Key people

Damien Seroux
Chairman of the Board, Chief Executive Officer · since 2014
Sophie Macault
Member of the Executive Committee, General Counsel and Corporate Secretary
Olivier Goze
Member of the Executive Committee and Director of Preclinical Operations
Pierre Bart
Director · since 2008
Monique Capron
Director · since 2006
Frederic Revah
Director · since 2008
IPO date
Mar 19, 2010
Employees
209
Domiciled in
FR
Incorporated in
FR
Headquarters & legal address
2 RUE DU PROFESSEUR GARGOUIL
CELLE-LEVESCAULT 86600
FR
Previous name
EUROFINS-CEREP

Valuation

Title
EUR in thousands, except ratios and share amounts
FY
2025‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT